A 6-year Follow-up of a Randomized Prospective Trial Comparing Methimazole Treatment with or without Exogenous L-thyroxine in Chinese Patients with Graves’ Disease

 

 Buy Article Permissions and Reprints

Abstract

Objective:  Antithyroid drug therapy is one of the main medical treatments for Graves’ disease. There have been conflicting reports as to whether the addition of exogenous L-thyroxine improves remission rates more than antithyroid drugs alone. This randomized, controlled and prospective clinical trial was undertaken to investigate the long-term outcome of methimazole treatment with or without exogenous L-thyroxine in Chinese patients.

Methods:  145 patients with Graves’ disease were randomly divided into 3 groups and all patients initially received 30 mg of methimazole daily for at least 1 month and then followed the titration ­regimen with or without L-thyroxine: group 1 (30 mg→20 mg→15 mg→10 mg→5 mg); group 2 (30 mg→20 mg→15 mg→10 mg+L-thyroxine→5 mg+L-thyroxine); group 3 (30 mg→20 mg→15 mg→10 mg+L-thyroxine→5 mg+L-thyroxine→2.5 mg+L-thyroxine). The drug therapy was discontinued after 5 months of the final dose.

Results:  16 out of 46 patients in group 1 (34.8%), 12 out of 47 in group 2 (25.5%) and 16 out of 52 in group 3 (30.8%) had a recurrence of Graves’ disease within 6-year follow-up after drug withdrawal. Survival Analysis showed no significant differences in the remission rates between any 2 groups, despite the remission rates in group 2 and 3 were slightly higher than that in group 1.

Conclusions:  The addition of L-thyroxine to methimazole treatment in patients with Graves’ disease neither improves nor prevents the remission or recurrence of Graves’ disease in China.

^* Co-first author.

• References

• 1 Weetman AP. Graves’ disease. N Engl J Med 2000; 343: 1236-1248
  CrossrefPubMedGoogle Scholar
• 2 Brent GA. Clinical practice. Graves’ disease. N Engl J Med 2008; 358: 2594-2605
  Google Scholar
• 3 Torring O, Tallstedt L, Wallin G et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine – a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81: 2986-2993
  CrossrefPubMedGoogle Scholar
• 4 Boelaert K. Treatment of Graves’ disease with antithyroid drugs: current perspectives. Thyroid 2010; 20: 943-946
  CrossrefPubMedGoogle Scholar
• 5 Hashizume K, Ichikawa K, Sakurai A et al. Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-953
  CrossrefPubMedGoogle Scholar
• 6 Tamai H, Hayaki I, Kawai K et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves’ disease patients. J Clin Endocrinol Metab 1995; 80: 1481-1484
  CrossrefPubMedGoogle Scholar
• 7 McIver B, Rae P, Beckett G et al. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220-224
  CrossrefPubMedGoogle Scholar
• 8 Rittmaster RS, Abbott EC, Douglas R et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves’ disease. J Clin Endocrinol Metab 1998; 83: 814-818
  CrossrefPubMedGoogle Scholar
• 9 Glinoer D, de Nayer P, Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001; 144: 475-483
  Google Scholar
• 10 Hoermann R, Quadbeck B, Roggenbuck U et al. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid 2002; 12: 1119-1128
  CrossrefPubMedGoogle Scholar
• 11 Wartofsky L, Glinoer D, Solomon B et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1991; 1: 129-135
  CrossrefPubMedGoogle Scholar
• 12 Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des 2001; 7: 451-460
  CrossrefPubMedGoogle Scholar
• 13 Leger J, Gelwane G, Kaguelidou F et al. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab 2012; 97: 110-119
  CrossrefPubMedGoogle Scholar
• 14 Laurberg P. Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism?. Eur J Endocrinol 2006; 155: 783-786
  Google Scholar